Abstract
Angiosarcoma is a malignant tumor originated in the vascular or lymphatic endothelium. As described in the literature under various names, angiosarcomas were previously called vascular endothelial tumor, ductal sarcoma, angiosarcoma, malignant hemangioendothelioma, and lymphatic sarcoma. It is now known as angiosarcoma, including vascular endothelial derived hemangiosarcoma and lymphangiosarcoma. Hemangiosarcoma cannot be differentiated from lymphangiosarcoma due to lack of reliable morphologic parameters and immunohistochemical features, so they are collectively referred to as angiosarcoma. Angiosarcoma is a rare tumor, commonly seen in skin and soft tissue, accounting for approximately 1–2% of soft tissue sarcoma. Retroperitoneal angiosarcoma is extremely rare as reported in the literature. In this chapter, etiological causes, histopathological features, immunohistochemical markers, clinical manifestation, treatment strategies, therapeutic efficacy, and prognostic factors of angiosarcoma will be briefly described.
References
Al-Abbadi MA, Almasri NM, Al-Quran S. Cytokeratin and epithelial membrane antigen expression in angiosarcomas: an immunohistochemical study of 33 cases. Arch Pathol Lab Med. 2007;131(2):288–92.
Asano Y, Makino T, Furuichi M. Effective treatment of angiosarcoma on the nose by combination treatment with electron beam irradiation, recombinant interleukin-2 and docetaxel. Clin Exp Dermatol. 2009;34(7):e227–8.
Colombo C, Randall RL, Andtbacka RH, Gronchi A. Surgery in soft tissue sarcoma: more conservative in extremities, more extended in the retroperitoneum. Expert Rev Anticancer Ther. 2012;12(8):1079–87.
Falk H, Herbert J, Crowley S, Ishak KG, Thomas LB, Popper H, Caldwell GG. Epidemiology of hepatic angiosarcoma in the United States: 1964-1974. Environ Health Perspect. 1981;41:107–13.
Fujimoto M, Kiyosawa T, Murata S. Vascular endothelial growth factor in angiosarcoma. Anticancer Res. 1998;18(5B):3725–9.
Girard C, Johnson WC, Graham JH. Cutaneous angiosarcoma. Cancer. 1970;26(4):868–83.
Hensley ML. Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas. Curr Opin Oncol. 2010;22(4):356–61.
Hingorani P, Eshun F, White-Collins A, Watanabe M. Gemcitabine, docetaxel, and bevacizumab in relapsed and refractory pediatric sarcomas. J Pediatr Hematol Oncol. 2012;34(7):524–7.
Hoshina D, Abe R, Yoshioka N, Saito N, Hata H, Fujita Y, Aoyagi S, Shimizu H. Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment. J Dermatol Sci. 2013;70(2):116–22.
Koontz BF, Miles EF, Rubio MA. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck. 2008;30(2):262–6.
Lejeune FJ, Pujol N, Liénard D. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol. 2000;26(7):669–78.
Lydiatt WM, Shaha AR, Shah JP. Angiosarcoma of the head and neck. Am J Surg. 1994;168(5):451–4.
Maddox JC, Evans HL. Angiosarcoma of skin and soft tissue: a study of forty-four cases. Cancer. 1981;48(8):1907–21.
McConnell EM, Haslam P. Angiosarcoma in post-mastectomy lymphoedema; a report of 5 cases and a review of the literature. Br J Surg. 1959;46(198):322–32.
Miettinen M. From morphological to molecular diagnosis of soft tissue tumors. Adv Exp Med Biol. 2006;587:99–113.
Naka N, Ohsawa M, Tomita Y. Prognostic factors in angiosarcoma: a multivariate analysis of 55 cases. J Surg Oncol. 1996;61(3):170–6.
Ohsawa M, Naka N, Tomita Y. Use of immunohistochemical procedures in diagnosing angiosarcoma. Evaluation of 98 cases. Cancer. 1995;75(12):2867–74.
Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol. 2010;22(4):351–5.
Penel N, Lansiaux A. Adenis a Angiosarcomas and taxanes. Curr Treat Options in Oncol. 2007;8(6):428–34.
Poblet E, Gonzalez-Palacios F, Jimenez FJ. Different immunoreactivity of endothelial markers in well and poorly differentiated areas of angiosarcomas. Virchows Arch. 1996;428(4-5):217–21.
Rosen A, Thimon S, Ternant D, Machet MC, Paintaud G, Machet L. Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face. Br J Dermatol. 2010;163(1):225–722.
Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer. 1948;1(1):64–81.
Trivers GE, Cawley HL, DeBenedetti VM. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst. 1995;87(18):1400–7.
Yoo C, Kim JE, Yoon SK. Angiosarcoma of the retroperitoneum: report on a patient treated with sunitinib. Sarcoma. 2009;2009:360875.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Liu, H., Miao, C. (2018). Retroperitoneal Angiosarcoma. In: Luo, CH. (eds) Retroperitoneal Tumors. Springer, Dordrecht. https://doi.org/10.1007/978-94-024-1167-6_24
Download citation
DOI: https://doi.org/10.1007/978-94-024-1167-6_24
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-024-1165-2
Online ISBN: 978-94-024-1167-6
eBook Packages: MedicineMedicine (R0)